UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New β-lactam-β-lactamase inhibitor combinations in clinical development

Annals of the New York Academy of Sciences, 2013-01, Vol.1277 (1), p.105-114

Shlaes, David M.

2013

Volltextzugriff (PDF)

The Economic Conundrum for Antibacterial Drugs

Antimicrobial agents and chemotherapy, 2019-12, Vol.64 (1)

Shlaes, David M

2019

Volltextzugriff (PDF)

Can Europe Pull It Together?

Clinical infectious diseases, 2020-11, Vol.71 (8), p.2000-2001

Shlaes, David M

2020

Volltextzugriff (PDF)

The FDA Reboot of Antibiotic Development

Antimicrobial agents and chemotherapy, 2013-10, Vol.57 (10), p.4605-4607

2013

Volltextzugriff (PDF)

Innovation, Nontraditional Antibacterial Drugs, and Clinical Utility

ACS infectious diseases, 2021-08, Vol.7 (8), p.2027-2028

Shlaes, David M

2021

Volltextzugriff (PDF)

Antibacterial Drugs: The Last Frontier

ACS infectious diseases, 2020-06, Vol.6 (6), p.1313-1314

Shlaes, David M.

2020

Volltextzugriff (PDF)

Eight more ways to deal with antibiotic resistance

Antimicrobial agents and chemotherapy, 2014-08, Vol.58 (8), p.4253-4256

2014

Volltextzugriff (PDF)

Personal View of the Antibiotic Value Proposition

ACS infectious diseases, 2020-06, Vol.6 (6), p.1315-1316

Shlaes, David M.

2020

Volltextzugriff (PDF)

Overcoming the challenges to developing new antibiotics

Current opinion in pharmacology, 2012-10, Vol.12 (5), p.522-526

2012

Volltextzugriff (PDF)

The pleuromutilin antibiotics: a new class for human use

Current opinion in investigational drugs (London, England : 2000), 2010-02, Vol.11 (2), p.182

2010

Volltextzugriff (PDF)

Antibiotics-From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about it

Pathogens & immunity, 2018, Vol.3 (1), p.19-43

2018

Volltextzugriff (PDF)

Mechanism of Action of the Mannopeptimycins, a Novel Class of Glycopeptide Antibiotics Active against Vancomycin-Resistant Gram-Positive Bacteria

Antimicrobial Agents and Chemotherapy, 2004-03, Vol.48 (3), p.728-738

2004

Volltextzugriff (PDF)

3,5-Dioxopyrazolidines, Novel Inhibitors of UDP-N- Acetylenolpyruvylglucosamine Reductase (MurB) with Activity against Gram-Positive Bacteria

Antimicrobial Agents and Chemotherapy, 2006-02, Vol.50 (2), p.556-564

2006

Volltextzugriff (PDF)

Reply to "Simple solutions reflect misunderstanding of animal antibiotic use"

Antimicrobial agents and chemotherapy, 2015-01, Vol.59 (1), p.751-751

2015

Volltextzugriff (PDF)

Research and Development of Antibiotics: The Next Battleground

ACS infectious diseases, 2015-06, Vol.1 (6), p.232-233

Shlaes, David M

2015

Volltextzugriff (PDF)

Further Evidence that a Cell Wall Precursor [C55-MurNAc-(Peptide)-GlcNAc] Serves as an Acceptor in a Sorting Reaction

Journal of Bacteriology, 2002-04, Vol.184 (8), p.2141-2147

2002

Volltextzugriff (PDF)

Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus

Biochimica et biophysica acta, 2003-05, Vol.1621 (2), p.117-121

2003

Volltextzugriff (PDF)

Antimicrobial Resistance in the 21st Century

2nd ed. 2018, 2018

Volltextzugriff (PDF)

Antibiotics—From There to Where?

Pathogens & immunity, 2018-02, Vol.3 (1), p.19-43

2018

Volltextzugriff (PDF)

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals

Clinical infectious diseases, 1997-09, Vol.25 (3), p.584-599

1997

Volltextzugriff (PDF)

Ceftazidime-Resistant Klebsiella pneumoniae Isolates Recovered at the Cleveland Department of Veterans Affairs Medical Center

Clinical infectious diseases, 1996-07, Vol.23 (1), p.118-124

1996

Volltextzugriff (PDF)

The abandonment of antibacterials: why and wherefore?

Current opinion in pharmacology, 2003-10, Vol.3 (5), p.470-473

Shlaes, David M

2003

Volltextzugriff (PDF)

5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of β-lactamases

Bioorganic & medicinal chemistry, 2008-02, Vol.16 (4), p.1890-1902

2008

Volltextzugriff (PDF)

In Memoriam: John P. Quinn, MD

Clinical infectious diseases, 2014-03, Vol.58 (5), p.748-750

2014

Volltextzugriff (PDF)

Telithromycin and the FDA: implications for the future

The Lancet infectious diseases, 2008-02, Vol.8 (2), p.83-85

2008

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Englisch
(122)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(79)
Humans
(49)
Infectious Diseases
(37)
Microbiology
(37)
Biological And Medical Sciences
(32)
Medical Sciences
(23)
Pharmacology & Pharmacy
(22)
Drug Resistance, Microbial
(19)
Immunology
(19)
Adult
(18)
Anti-Bacterial Agents - Pharmacology
(17)
Microbial Sensitivity Tests
(17)
Antibiotics
(16)
Infections
(16)
Middle Aged
(16)
Pharmacology. Drug Treatments
(16)
Anti-Bacterial Agents - Therapeutic Use
(15)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(15)
Male
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

New β-lactam-β-lactamase inhibitor combinations in clinical development

The Economic Conundrum for Antibacterial Drugs

Can Europe Pull It Together?

The FDA Reboot of Antibiotic Development

Innovation, Nontraditional Antibacterial Drugs, and Clinical Utility

Antibacterial Drugs: The Last Frontier

Eight more ways to deal with antibiotic resistance

Personal View of the Antibiotic Value Proposition

Overcoming the challenges to developing new antibiotics

The pleuromutilin antibiotics: a new class for human use

Antibiotics-From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about it

Mechanism of Action of the Mannopeptimycins, a Novel Class of Glycopeptide Antibiotics Active against Vancomycin-Resistant Gram-Positive Bacteria

3,5-Dioxopyrazolidines, Novel Inhibitors of UDP-N- Acetylenolpyruvylglucosamine Reductase (MurB) with Activity against Gram-Positive Bacteria

Reply to "Simple solutions reflect misunderstanding of animal antibiotic use"

Research and Development of Antibiotics: The Next Battleground

Further Evidence that a Cell Wall Precursor [C55-MurNAc-(Peptide)-GlcNAc] Serves as an Acceptor in a Sorting Reaction

Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus

Antimicrobial Resistance in the 21st Century

Antibiotics—From There to Where?

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals

Ceftazidime-Resistant Klebsiella pneumoniae Isolates Recovered at the Cleveland Department of Veterans Affairs Medical Center

The abandonment of antibacterials: why and wherefore?

5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of β-lactamases

In Memoriam: John P. Quinn, MD

Telithromycin and the FDA: implications for the future

Suchergebnisse filtern